印度 HPV（人類乳突病毒）疫苗市場評估：依類型、適應症、合成、分銷管道和地區劃分的機會和預測（2017-2031 年）

根據預測，印度HPV（人類乳突病毒）疫苗市場規模將從2023年的13億美元成長到2031年的30億美元，2024-2031年預測期間複合年增長率為11%。

有幾個因素促使了市場規模的擴大，包括由於子宮頸癌和其他 HPV 相關疾病的盛行率不斷增加，人們對 HPV 疫苗接種重要性的認識不斷提高。此外，政府主導的各種措施、疫苗接種計劃和疫苗開發技術的進步在提高疫苗接種意識方面發揮著重要作用。

近年來，由於人們對預防 HPV 感染及相關疾病重要性的認識不斷提高，印度 HPV 疫苗市場經歷了顯著增長。子宮頸癌是影響印度數百萬女性的主要原因，主要與 HPV（一種常見的性傳染感染）有關。人們越來越認識到 HPV 疫苗的好處及其減輕子宮頸癌負擔的潛力，促使印度對 HPV 疫苗的需求激增。為此，印度政府和各醫療機構實施了一系列措施和疫苗接種計劃，以加速疫苗的接種，特別關注年輕婦女和女孩。

此外，隨著疫苗開發技術的進步，印度 HPV 市場有望推出更有效、更容易取得的疫苗。這些突破讓醫療保健提供者和個人對 HPV 疫苗接種的有效性和安全性充滿了信心。HPV 疫苗在印度日益普及，標誌著全國在對抗 HPV 感染和保護婦女福祉的努力中取得了可喜的進展，對印度 HPV 疫苗市場產生了積極影響。

2023 年 12 月，印度計劃生育協會 (FPAI) 發起了全國性 HPV 疫苗接種運動，以保護女孩和婦女免受子宮頸癌的侵害。該活動旨在透過 FPAI 遍佈全國的 40 個分支機構為 20,000 多名婦女和女孩接種疫苗。

本報告調查了印度 HPV（人類乳突病毒）疫苗市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。格局、領導企業簡介等等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第 3 章執行摘要

第四章 印度HPV（人類乳突病毒）疫苗市場展望

• 市場規模/預測
• 依類型
  • 二價
  • 四價
  • 非價的
• 依指示
  • 子宮頸癌
  • 肛門癌
  • 外陰/陰道癌
  • 陰莖癌
  • 口咽癌
  • 其他
• 依合成方法
  • 基於核酸的
  • 基於勝□的
  • 基於蛋白質的
  • 基於細胞的
  • 活載體疫苗
• 依分銷渠道
  • 醫院
  • 零售藥店
  • 網上藥店
  • 非政府組織
• 依地區
  • 北方
  • 南部
  • 東
  • 西部/中部地區
• 依公司劃分的市場佔有率

第 5 章 市場測繪

• 依類型
• 依疾病分類
• 依合成方法
• 依分銷渠道
• 依地區

第六章 宏觀環境與產業結構

• 供需分析
• 進出口分析
• 價值鏈分析
• PESTEL 分析
• 波特五力分析

第七章市場動態

• 生長促進因子
• 生長抑制因素（問題/限制）

第八章 監理框架與創新

• 臨床試驗
• 專利情況
• 監管審批
• 創新/新興技術

第九節 主要公司狀況

• 前 5 名市場領導者的競爭矩陣
• 前 5 名市場領導者的市場收入分析
• 併購/合資（如適用）
• SWOT分析（5家參與企業）
• 專利分析（如果適用）

第10章價格分析

第11章案例研究

第十二章 主要公司展望

• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Beijing Health Guard Biotechnology, Inc.
• China National Biotec Group Company Limited
• Shanghai Bovax Biotechnology Co., Ltd.
• Walvax Biotechnology Co., Ltd
• Xiamen Innovax Biotech Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Eyegene Inc.
• Janssen Biotech, Inc.

第十三章 戰略建議

第14章關於我們公司/免責聲明

India human papillomavirus vaccine market is projected to witness a CAGR of 11% during the forecast period FY2024-FY2031, growing from USD 1.3 billion in FY2023 to USD 3 billion in FY2031. Several factors are contributing to the growing market size, including a rise in awareness about the importance of HPV vaccination due to the increasing prevalence of cervical cancer and other diseases associated with HPV. In addition, various government-led initiatives and vaccination programs, as well as advancements in vaccine development technology, have played a crucial role in increasing awareness about vaccination.

In recent years, India human papillomavirus vaccine market has experienced substantial growth, driven by an increasing recognition of the significance of preventing HPV infections and their associated diseases. Cervical cancer, a leading cause of concern for millions of women in India, is primarily linked to HPV, a common sexually transmitted infection. The increasing awareness about the benefits of HPV vaccination and its potential to reduce the burden of cervical cancer has resulted in a surge in demand for HPV vaccines in India. In response, the Indian government and various healthcare organizations have undertaken numerous initiatives and vaccination programs to promote widespread vaccine adoption, with a particular focus on young girls and women.

Furthermore, advancements in vaccine development technology have paved the way for the introduction of more effective and accessible vaccines in India human papillomavirus vaccine market. These breakthroughs have instilled confidence among healthcare providers and individuals regarding the efficacy and safety of HPV vaccination. The rising popularity of HPV vaccines in India signals a promising step forward in the effort to combat HPV infections and safeguard the well-being of women across the country, positively impacting the India human papillomavirus vaccine market.

In December 2023, the Family Planning Association of India (FPAI) initiated a nationwide HPV vaccination drive for girls and women to protect them against cervical cancer. The campaign's objective is to vaccinate over 20,000 women and girls through the FPAI's 40 branches spread across the country.

Increasing Awareness About HPV Immunization

Increasing awareness about the importance of HPV vaccination has led to significant growth of India human papillomavirus vaccine market. While efforts implemented by governments and healthcare organizations have increased screening for cervical cancer, the primary prevention achieved through HPV immunization has played a crucial role in diminishing the cervical cancer burden in India. The effectiveness of these strategies has been evident not only in high-income countries (HICs) but has also resulted in higher rates of adoption of the HPV vaccine and widespread approval in low- and lower-middle-income countries (LLMICs). International collaborations between WHO, United Nations Population Fund, UN Women, and the IPVS (Indian Post Visibility System), along with healthcare providers who are trusted sources of health advice, persist in their efforts to inform and promote HPV immunization. In the context of school-based vaccination programs, educators, school administrators, and the Ministry of Education also play a crucial role in conveying the advantages of HPV vaccination.

Increasing Incidence of HPV-related diseases

According to the National Cancer Registry Programme of the Indian Council of Medical Research, the estimated number of cervical cancer cases in India was over 340,000 in 2023. The incidence will further increase in the coming years because of factors such as smoking and excessive alcohol consumption, urbanization and changing lifestyles, delayed childbearing and multiple sexual partners, limited access to quality healthcare and diagnostic facilities in certain regions of India, and cultural taboos and stigmatization of certain cancers and sexually transmitted infections. This way, increasing incidences of HPV-related diseases will continue to have a positive effect on India human papillomavirus vaccine market.

Government Initiatives

Government initiatives has greatly influenced the India human papillomavirus vaccine market. The Indian government has taken proactive and comprehensive measures to tackle the public health challenge posed by human papillomavirus (HPV) infections. The primary goal of these initiatives is to increase awareness about the advantages of HPV vaccination and ensure broad vaccine coverage, with a specific focus on young girls and women. In addition to conducting awareness campaigns, the government has initiated vaccination programs and several educational initiatives to distribute information about HPV, its risks, and preventive measures.

In December 2022, the National Technical Advisory Group for Immunization (NTAGI) recommended the inclusion of the HPV vaccine in the Universal Immunization Programme (UIP). The plan involved a one-time catch-up vaccination for 9-14-year-old adolescent girls, followed by routine introduction at 9 years of age. To facilitate this vaccination drive, schools played a significant role in the implementation, adopting a grade-based approach for girls in 5th to 10th grades.

Quadrivalent Vaccines are Witnessing Rapid Growth in Demand

Increasing demand for quadrivalent vaccines has caused growth in India human papillomavirus vaccine market. The quadrivalent HPV vaccine consists of a combination of four HPV type-specific Virus-Like Particles (VLPs) derived from HPV 6, 11, 16, and 18 L1 proteins, along with an aluminum adjuvant. Clinical trials have demonstrated the vaccine's remarkable efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 in females who have not been previously infected with the respective HPV type. It is essential to note that the vaccine does not offer protection against diseases caused by HPV types that females may already be infected with at the time of vaccination. Gardasil, a quadrivalent vaccine developed by Merck & Co. in October 2022, revealed the initial results of the clinical trial to test for two versus three doses of Gardasil vaccine in India. The clinical trials were carried out by All India Institute of Medical Sciences, New Delhi, in collaboration with several other institutes and hospitals.

High Prevalence and Government Initiatives for HPV in Eastern Region

In the Eastern region, cervical cancer is growing at a rapid rate. The district of Papumpare in the Indian state of Arunachal Pradesh has the highest incidence rate of cervical cancer (AAR-27.7) in Asia, according to the National Cancer Registry Programme. Mizoram's Aizawl district came next, with an incidence of AAR-27.3, followed by Arunachal Pradesh's Pasighat district, with an incidence of AAR-20.3. To reduce the prevalence of HPV, the central and state governments have started various initiatives aimed towards increasing awareness about HPV and increasing immunization drives. For example, Sikkim state made a landmark decision to be the first state in India to introduce HPV vaccine statewide. In June 2023, the Union Health Ministry administered the human papillomavirus (HPV) vaccine in the Mizoram state as a part of the universal immunization program.

Future Market Scenario (2024 - 2031F)

Increased awareness and education campaigns regarding the link between HPV and cervical cancer in India are expected to boost the adoption rate of the vaccine in the India human papillomavirus vaccine market.

The India human papillomavirus vaccine market may be greatly impacted by the government's efforts to promote HPV vaccination, whether by including it in national immunization programs or by providing financial assistance.

Future advancements in vaccination science may lead to the development of HPV vaccinations that offer protection against new virus strains. As a result, the India human papillomavirus vaccine market may become more effective, increasing their public appeal, and maybe expanding the age range of individuals who can receive vaccinations.

Collaboration between vaccine producers, authorities, non-governmental organizations, and healthcare professionals in the India human papillomavirus vaccine market may expand the availability of HPV vaccines throughout the country, particularly in rural and impoverished areas.

Key Players Landscape and Outlook

India human papillomavirus vaccine market is undergoing a notable transformation, marked by a rising trend of mergers and collaborations among pharmaceutical firms and research institutions. These strategic partnerships are emerging as pivotal catalysts propelling the progress of HPV vaccine development, production, and distribution in India. Considering the increasing demand for HPV vaccines and the mounting recognition of their significance in cervical cancer and HPV-linked ailments, notable players within India's pharmaceutical sector are embracing the potency of collaboration.

For instance, in January 2023, India celebrated a significant milestone with the launch of its first domestically developed Quadrivalent Human Papillomavirus vaccine (qHPV) named 'CERVAVAC.' This achievement was made possible through a collaborative effort between the Serum Institute of India (SII), the Department of Biotechnology (DBT), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation. 'CERVAVAC' promises to play a crucial role in preventing HPV infections and associated diseases.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. India Human Papillomavirus Vaccine Market Outlook, FY2017-FY2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type
  • 4.2.1. Bivalent
  • 4.2.2. Quadrivalent
  • 4.2.3. Nonavalent
• 4.3. By Disease indication
  • 4.3.1. Cervical cancer
  • 4.3.2. Anal cancer
  • 4.3.3. Vulvar & Vaginal cancer
  • 4.3.4. Penile cancer
  • 4.3.5. Oropharyngeal cancer
  • 4.3.6. Others
• 4.4. By Method of Synthesis
  • 4.4.1. Nucleic acid-based
    • 4.4.1.1. DNA
    • 4.4.1.2. mRNA
  • 4.4.2. Peptide-based
  • 4.4.3. Protein-based
  • 4.4.4. Cell-based
  • 4.4.5. Live vector vaccine
• 4.5. By Distribution Channel
  • 4.5.1. Hospital
  • 4.5.2. Retail Pharmacy
  • 4.5.3. Online Pharmacy
  • 4.5.4. Non-Governmental Organizations
• 4.6. By Region
  • 4.6.1. North
  • 4.6.2. South
  • 4.6.3. East
  • 4.6.4. West and Central
• 4.7. By Company Market Share (%), FY2023

5. Market Mapping, FY2023

• 5.1. By Type
• 5.2. By Disease Indication
• 5.3. By Method of Synthesis
• 5.4. By Distribution Channel
• 5.5. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors (Challenges and Restraints)

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. Regulatory Approvals
• 8.4. Innovations/Emerging Technologies

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Appliable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. GlaxoSmithKline Plc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Merck & Co., Inc.
• 12.3. Beijing Health Guard Biotechnology, Inc.
• 12.4. China National Biotec Group Company Limited
• 12.5. Shanghai Bovax Biotechnology Co., Ltd.
• 12.6. Walvax Biotechnology Co., Ltd
• 12.7. Xiamen Innovax Biotech Co., Ltd.
• 12.8. Serum Institute of India Pvt. Ltd.
• 12.9. Eyegene Inc.
• 12.10. Janssen Biotech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Human Papillomavirus Vaccine Market, By Value, in USD Billion, FY2017-FY2031F
• Figure 2. India Human Papillomavirus Vaccine Market, By Volume, in Thousand Units, FY2017-FY2031F
• Figure 3. India Human Papillomavirus Vaccine Market Share (%), By Type, FY2017-FY2031F
• Figure 4. India Human Papillomavirus Vaccine Market Share (%), By Disease Indication, FY2017-FY2031F
• Figure 5. India Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, FY2017-FY2031F
• Figure 6. India Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, FY2017-FY2031F
• Figure 7. India Human Papillomavirus Vaccine Market Share (%), By Region, FY2017-FY2031F
• Figure 8. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 9. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 10. By Method of Synthesis Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 11. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 12. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2023